Abstract: Serotonin neurons modulate most homeostatic Central Nervous System (CNS) functions while influencing the expression of behavioral traits such as mood, aggression and anxiety. Serotonin neuron dysfunction has been implicated in depression, addiction, autism and sudden infant death syndrome. This disclosure describes a straightforward, highly reproducible method for genetically accessing serotonin neurons and a sub-population of intestinal enterocytes, in vivo, using BAC-based transgenes that can be constructed using simple subcloning procedures. Compositions described herein include these transgenes and methods for making and using them to create transgenic mouse strains and identify serotonin and intestinal enterocytes without immunostaining.

Abstract: Serotonin neurons modulate most homeostatic Central Nervous System (CNS) functions while influencing the expression of behavioral traits such as mood, aggression and anxiety. Serotonin neuron dysfunction has been implicated in depression, addiction, autism and sudden infant death syndrome. This disclosure describes a straightforward, highly reproducible method for genetically accessing serotonin neurons and a sub-population of intestinal enterocytes, in vivo, using BAC-based transgenes that can be constructed using simple subcloning procedures. Compositions described herein include these transgenes and methods for making and using them to create transgenic mouse strains and identify serotonin and intestinal enterocytes without immunostaining.

Abstract: The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.

Abstract: The present invention discloses a new neuronal nicotinic acetylcholine receptor subunit, .beta.4. The new subunit can form functional combinations with other neuronal nicotinic acetylcholine receptor subunits, including, but not limited to, alpha2, alpha3, alpha4 and beta2. A cDNA clone containing the DNA sequences that encode the novel receptor subunit of the invention has been deposited with the American Type Culture Collection for patent purposes.

Abstract: The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.